Compare Boston Beer Company Inc (SAM) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Beer Company Inc vs Sanofi SA — how do they compare? Boston Beer Company Inc trades at $163.71 (market cap $1.67B), while Sanofi SA trades at $43.12 (market cap $104.06B). The key difference: Sanofi SA is far larger — about 62.3× Boston Beer Company Inc's market cap, and Sanofi SA pays a 5.61% dividend while Boston Beer Company Inc pays none. Which is the better fit depends on your goals.
| SAM | SNY | |
|---|---|---|
Market Cap | $1.67B | $104.06B |
Sector | Consumer Staples | Health |
52-Week High | $260.05 | $52.34 |
52-Week Low | $161.08 | $41.33 |
Enterprise Value | $1.43B | $124.09B |
Dividend Yield | — | 5.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The Boston Beer Company (SAM) trades at $162.06, down 3.98% today, showing mixed signals with bearish technical indicators but positive cash flow trends. Recent earnings have missed expectations in Q1 and Q2 2026, though Q4 2025 beat estimates. The company maintains a debt-free balance sheet with strong operating cash flow of $270M in 2025, but faces volume declines and margin pressure.
SAM presents a cautious outlook with analyst consensus leaning Hold (71.87%) despite a $207.33 price target suggesting 28% upside. Key risks include declining alcohol consumption and execution challenges, while opportunities lie in new product launches and marketing leadership changes. The stock's valuation appears reasonable with P/E of 22.66 and P/S of 0.89.
Sanofi (SNY) trades at $43.155, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported strong Q2 2026 earnings, beating expectations with EPS of $1.21 versus $1.10 expected, and raised full-year guidance. Recent FDA approvals for COVID vaccines and EU approval for MenQuadfi in infants provide positive catalysts, though pipeline setbacks with an eczema drug withdrawal create uncertainty.
SNY presents a mixed outlook with solid fundamentals including a 5.4% dividend yield and reasonable valuation (P/E 22.94), but faces execution risks under new CEO leadership. Analyst consensus leans Hold (51.86%) with price target of $49.50, suggesting moderate upside potential. Key risks include drug pipeline challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
